## Zmyome<sup>®</sup> Proactive Health SINGLE-GENE RISK™

# **Understanding Test Results**

The MyOme<sup>®</sup> Proactive Health Single-Gene Risk<sup>™</sup> test analyzes genes linked to adult onset, actionable conditions, such as cardiac disease and cancer, to support early detection or reduced risk of developing the disease.



## **Test Result Overview**

### **Positive Result**

A pathogenic or likely pathogenic variant was found in one of the genes analyzed, suggesting an increased risk for the associated condition(s).



#### Interventions may be necessary to manage the risk, including:

#### **INCREASED SURVEILLANCE**

More frequent screening or monitoring for the associated condition.



#### **PREVENTIVE INTERVENTIONS**

 Lifestyle modifications or medications aimed at reducing risk.

#### -

**GENE INFORMATION** 

VARIANT The specific genetic variant detected.

The gene in which the variant was identified.

#### ZYGOSITY

How many copies of the variant were detected: heterozygous (one) or homozygous (two).

#### **CLINICAL INFORMATION**

Brief overview of the disease and risks associated with the genetic variant detected.

#### **SPECIALIST REFERRAL**

Referral to a genetic counselor or specialist for further assessment and personalized risk management.

**CONTINUE MONITORING** 

General population screening

is still indicated.

### **Negative Result**

No known pathogenic or likely pathogenic variants were found in the genes analyzed.

A negative result does not eliminate the risk of the patient developing any of the associated conditions. The test may not cover all genes or genetic variants associated with a particular condition. A patient's family history, lifestyle, and environment should also be considered.\* Ð

## \*Increased clinical screening or diagnostic genetic testing may be necessary for patients with a personal or family history of an inherited condition included in the test.



## Zmyome<sup>®</sup> Proactive Health SINGLE-GENE RISK™



## **Positive Result Next Steps**

- A positive result is medically actionable.
- Family members may be at increased risk for this variant.
- Patients should share results with their family.
- Genetic testing can identify who may benefit from increased screening and care.



A patient has a positive result with a pathogenic variant in the MYH7 gene associated with hypertrophic cardiomyopathy (HCM). Patients at risk for HCM should be referred to cardiology for screening, typically including echocardiogram and follow-up per cardiology recommendations.



## **Negative Result Next Steps**

- Negative results should be considered alongside clinical findings, family history, and other data.
- A negative result doesn't rule out unique risks for family members.
- Family members may benefit from genetic testing to assess their disease risk.



Genetic counseling can help address any questions you or your patients have about test results and personal or family medical history.



## **MyOme Gene List**

A complete list of the genes in the MyOme<sup>®</sup> Proactive Health<sup>™</sup> screening test is available at **www.myome.com/proactive-health**.



Make MyOme Proactive Health part of your clinical care. Contact <u>support@myome.com</u> to get started.

The test described above was developed and its performance characteristics were determined by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high-complexity clinical laboratory testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). College of American Pathologists (CAP) accredited and CLIA certified.